PeptiDream (TSE:4587) just logged two meaningful scientific wins, advancing an oral dual IL 17 program into its clinical portfolio and hitting a preclinical siRNA delivery milestone with Alnylam, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback